Email this article MEDICINES OF MONOCLONAL ANTIBODIES IN ONCOLOGY
- Authors: Avdeeva Z.I.1, Soldatov A.A.1, Kiselevskiy M.V.2, Bondarev V.P.1
-
Affiliations:
- Scientific Centre for Expert Evaluation of Medicinal Products
- Russian Cancer Research Center named after N. N. Blokhin» of the of the Ministry of Health of the Russian Federation
- Issue: Vol 22, No 2-1 (2019)
- Pages: 133-135
- Section: ORIGINAL ARTICLES
- URL: https://rusimmun.ru/jour/article/view/21
- DOI: https://doi.org/10.31857/S102872210006426-3
- ID: 21
Cite item
Full Text
Abstract
The medicines of monoclonal antibody which are successfully applied in clinical practice to treatment of oncological diseases are result of scientific achievements of biotechnology developments and researches in the field of molecular immunology. However, despite efficiency of use of the specified biotherapeutic drugs, remains many unresolved questions evolving when developing new medicines from recombinant proteins and at their clinical use. It is connected with the choice of a target antigen taking into account carcinogenesis mechanisms when developing medicine, comprehensive assessment of qualitative characteristics of recombinant protein, providing appropriate conditions of production, assessment of safety of a clinical use connected, first of all, with manifestations of «undesirable» immunogenicity of medicine.
About the authors
Zh. I. Avdeeva
Scientific Centre for Expert Evaluation of Medicinal Products
Author for correspondence.
Email: avd-cytok@yandex.ru
PhD, professor, Chief Expert of Office of expertise allergens, cytokines and other immunomodulators,
Moscow
Russian FederationA. A. Soldatov
Scientific Centre for Expert Evaluation of Medicinal Products
Email: fake@neicon.ru
PhD, Chief Expert of Office of expertise allergens, cytokines and other immunomodulators,
Moscow
Russian FederationM. V. Kiselevskiy
Russian Cancer Research Center named after N. N. Blokhin» of the of the Ministry of Health of the Russian Federation
Email: fake@neicon.ru
PhD, professor, Head of the laboratory of cellular immunity,
Moscow
Russian FederationV. P. Bondarev
Scientific Centre for Expert Evaluation of Medicinal Products
Email: fake@neicon.ru
PhD, professor, Director,
Moscow
Russian FederationReferences
- Teng M. W., Galon J., Fridman W. H., Smyth M. J. From mice to humans: developments in cancer immunoediting. J Clin Invest. 2015 Sep; 125(9):3338–46. doi: 10.1172/JCI80004. PMID: 26241053.
- Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480(7378): 480–9.
- Vannemann M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Rev Cancer. 2012; 12: 237–50.
- Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 2002; 24: 1720–40.
- Bartelds G. M., Krieckaert C. L., Nurmohamed M. T., van Schouwenburg P. A., Lems W. F., Twisk J. W., Dij kmans B. A., Aarden L., Wolbink G. J. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305: 1460–8.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).